![Card image cap](https://i0.wp.com/docmode.org/wp-content/uploads/2022/05/expertsinindia.png?fit=1071%2C675&ssl=1)
Budesonide helps reducing risk of pneumonia and death in COPD
Budesonide-based triple therapy is effective in reducing the risk of severe pneumonia and death in COPD patients, especially in those with higher blood eosinophil count, reveals a recent research. The findings of the study, published in the Journal of Chronic Obstructive Pulmonary Disease, used data from 29,716 new users of fluticasone-based triple therapy and 9646 new users of budesonide-based triple therapy, from the Clinical Practice Research Datalink. The research found that the incidence of a moderate or severe exacerbation and all-case death incidence was lower with budesonide-based triple therapy.